Literature DB >> 7364321

Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.

S Madsbad, B Bjerregaard, J H Henriksen, E Juhl, H Kehlet.   

Abstract

Fourteen patients with liver cirrhosis received oral prednisone or prednisolone (0.3 mg per kg) randomised on two consecutive days. Serum prednisone and prednisolone were measured over the following four hours. Mean serum prednisolone concentration after oral prednisone decreased with impaired liver function estimated by galactose elimination capacity (r = 0.64, P less than 0.03). Mean serum prednisolone concentration after oral prednisone in the seven patients with severely impaired liver function was only 53% (P less than 0.05) of that observed in the seven patients with slightly impaired liver function. Conversely, mean serum prednisone concentration after oral prednisone in the patients with severely impaired liver function was 74% higher (P = 0.05) than in patients with slightly impaired liver function. Mean serum prednisolone after oral prednisolone was independent of liver function. As only prednisolone exerts glucocorticoid activity, our results indicate that prednisolone should be preferred to prednisone in the treatment of patients with impaired liver function.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7364321      PMCID: PMC1419565          DOI: 10.1136/gut.21.1.52

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  14 in total

1.  Controlled trial of prednisone and azathioprine in active chronic hepatitis.

Authors:  I M Murray-Lyon; R B Stern; R Williams
Journal:  Lancet       Date:  1973-04-07       Impact factor: 79.321

2.  Clearance of antipyrine-dependence of quantitative liver function.

Authors:  P B Andreasen; L Ranek; B E Statland; N Tygstrup
Journal:  Eur J Clin Invest       Date:  1974-04       Impact factor: 4.686

3.  Radioimmunoassay for prednisolone.

Authors:  W A Colburn; R H Buller
Journal:  Steroids       Date:  1973-06       Impact factor: 2.668

4.  Radioimmunoassay for prednisone.

Authors:  W A Colburn
Journal:  Steroids       Date:  1974-07       Impact factor: 2.668

5.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

Authors:  W H Summerskill; M G Korman; H V Ammon; A H Baggenstoss
Journal:  Gut       Date:  1975-11       Impact factor: 23.059

6.  Conversion of cortisone to cortisol and prednisone to prednisolone.

Authors:  J S Jenkins; P A Sampson
Journal:  Br Med J       Date:  1967-04-22

7.  Galactose elimination capacity as a prognostic index in patients with fulminant liver failure.

Authors:  L Ranek; P B Andreasen; N Tygstrup
Journal:  Gut       Date:  1976-12       Impact factor: 23.059

8.  Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability.

Authors:  M Davis; R Williams; J Chakraborty; J English; V Marks; G Ideo; S Tempini
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

9.  Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding.

Authors:  L W Powell; E Axelsen
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

10.  Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.

Authors:  S W Schalm; W H Summerskill; V L Go
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

View more
  6 in total

1.  Systemic steroids in chronic severe asthma.

Authors:  L D Lewis; G M Cochrane
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-17

Review 2.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Ulcerative colitis: an overview.

Authors:  A Archambault
Journal:  Can Fam Physician       Date:  1990-02       Impact factor: 3.275

Review 4.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

5.  Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease.

Authors:  M Uribe; W H Summerskill; V L Go
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

6.  Prednisolone Delivery Platforms: Capsules and Beads Combination for a Right Timing Therapy.

Authors:  Andrea Cerciello; Giulia Auriemma; Silvana Morello; Rita P Aquino; Pasquale Del Gaudio; Paola Russo
Journal:  PLoS One       Date:  2016-07-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.